The 2020 updates to the NCCN Guidelines for Rectal Cancer reflect advancements in treatment paradigms. Notably, the guidelines clarify the definition of rectal cancer and endorse total neoadjuvant therapy for localized disease. Furthermore, the integration of biomarker-targeted therapy for metastatic colorectal cancer underscores a shift towards personalized medicine, optimizing therapeutic outcomes and informing future research directions in rectal cancer management.